Scholarlink

<p>Major depressive disorder (MDD) is a heterogeneous disease with complex etiology, accompanied by high morbidity and disability. Recently, neuroinflammation has been identified as a crucial mechanism in major depressive disorder. Mangiferin (MGF) is a natural flavonoid polyphenolic compound primarily extracted from Anemarrhenae Rhizome or mango that exhibits promising anti-inflammatory activity in the preclinical treatment of MDD. The present research used network pharmacology and bioinformatics to identify 3 core targets (ICAM1, MAPK3, and MMP9) associated with MGF for treating neuroinflammation in MDD. We have identified MDD as being closely associated with immunity and neuroinflammation, with core targets primarily related to calcium and the NOD-like receptor signaling pathway, among others. Based on molecular docking studies, MGF has good binding activity with MAPK and MMP9. This research suggests that MGF has the potential to treat neuroinflammation in MDD, providing a basis for further exploration of its clinical application in treating neuroinflammation associated with MDD.</p> Graphical Abstract <p></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Molecular Mechanisms of Mangiferin on Neuroinflammation for Treating Major Depressive Disorder Based on Network Pharmacology and Bioinformatics Analysis

  • 期刊论文

  • 发表日期：

    2026年3月14日

查看全文
  • Cong-Ya Chen,
  • Lan Lei,
  • Xuan Yang,
  • Yu-Fei Wang,
  • Yi Zhang

摘要

Major depressive disorder (MDD) is a heterogeneous disease with complex etiology, accompanied by high morbidity and disability. Recently, neuroinflammation has been identified as a crucial mechanism in major depressive disorder. Mangiferin (MGF) is a natural flavonoid polyphenolic compound primarily extracted from Anemarrhenae Rhizome or mango that exhibits promising anti-inflammatory activity in the preclinical treatment of MDD. The present research used network pharmacology and bioinformatics to identify 3 core targets (ICAM1, MAPK3, and MMP9) associated with MGF for treating neuroinflammation in MDD. We have identified MDD as being closely associated with immunity and neuroinflammation, with core targets primarily related to calcium and the NOD-like receptor signaling pathway, among others. Based on molecular docking studies, MGF has good binding activity with MAPK and MMP9. This research suggests that MGF has the potential to treat neuroinflammation in MDD, providing a basis for further exploration of its clinical application in treating neuroinflammation associated with MDD.

Graphical Abstract